Share

Comments on:

Manhattan Moment: FDA overreach has heavy costs

Back to the article » |
On Nov. 22, the Food and Drug Administration flexed its regulatory muscles by sending a warning letter to a genetic-testing company that goes under the stylish name of 23andme. The company was selling to the general public a $99 saliva-based test that could give customers information about some 240 genetic traits, which relate to a wide range of disease conditions. The FDA wants to evaluate...

To learn more about commenting on WashingtonExaminer.com and our community guidelines, please see our comments FAQ.